Ad5FGF-4
Ad5FGF-4 Uses, Dosage, Side Effects, Food Interaction and all others data.
Ad5FGF-4, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease. Ad5FGF-4 represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard cardiac infusion catheter.
| Trade Name | Ad5FGF-4 |
| Generic | Alferminogene tadenovec |
| Alferminogene tadenovec Other Names | Ad5FGF-4, Alferminogene tadenovec |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in angina, coronary artery disease, and heart disease.
How Ad5FGF-4 works
Ad5FGF-4 holds the potential to promote a disease-modifying improvement by leveraging the body’s natural healing processes in response to myocardia ischemia (insufficient blood flow and myocardial oxygen supply). Angiogenesis, the growth of new collateral blood vessels, is a natural biologic response to repeated myocardial ischemia. These newly formed vessels provide alternate routes of blood flow and oxygen delivery to parts of the patient’s heart downstream from a blockage in a coronary artery. In many patients however, including those with recurrent angina, coronary collateral vessel formation is insufficient to meet the heart’s needs during stress. Currently available anti-anginal drugs, which may provide symptomatic relief, are generally designed to alter the oxygen demand of the heart muscle or dilate vessels to temporarily relieve angina. Ad5FGF-4 is designed to promote the heart’s natural response of collateral growth and to increase blood flow in the microcirculation.
Innovators Monograph
You find simplified version here Ad5FGF-4
